cyclophosphamide + epirubicin + fluorouracil + paclitaxel + zoledronic acid

This is a combination therapy used primarily for breast cancer treatment, especially in cases with bone metastases. The regimen combines three components: 1. FEC/CEF (fluorouracil, epirubicin, cyclophosphamide) - an anthracycline-based chemotherapy combination 2. Paclitaxel (taxane) - often given sequentially after EC (epirubicin and cyclophosphamide) 3. Zoledronic acid - a bisphosphonate that strengthens bones and prevents skeletal complications The chemotherapy components target rapidly dividing cancer cells through different mechanisms, while zoledronic acid inhibits osteoclast-mediated bone resorption, reducing bone pain and skeletal-related events in patients with bone metastases.